-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In randomized controlled trials, adjuvant radiotherapy did not show the potential to reduce progression-free survival compared with early rescue radiotherapy (sRT) after radical prostatectomy (RP)
In this study, Derya et al.
Adjusted risk assessment of all-cause death: A) 2424 patients with pathological dysfunction in pN1 stage; B) 933 patients with pathological dysfunction in pN1 stage; C) 23694 patients with pathological dysfunction
Adjusted risk assessment of all-cause death: A) 2424 patients with pathological dysfunction in pN1 stage; B) 933 patients with pathological dysfunction in pN1 stage; C) 23694 patients with pathological dysfunctionAfter a median follow-up of 8.
After a median follow-up of 8.
Prostate cancer patients with pN1 stage or pGleason score 8-10 points and pT3/4 stage may consider adjuvant radiotherapy, which is expected to significantly reduce their risk of all-cause death pN1 stage or pGleason score 8-10 points and pT3/4 stage Prostate cancer patients may consider adjuvant radiotherapy, which is expected to significantly reduce the risk of all-cause death
Original source:
Original source:Derya Tilki, et al.
Leave a message here